Learning Studios, symposia offer latest advances

Learning Studios and symposia provide a unique opportunity for companies in the field of cardiology to share their latest advances in cardiovascular practices, services and technologies.


Getty Images 1185375000 2

Here are the opportunities that will be presented at Scientific Sessions. Check the Mobile App for updates and a complete list of programming. (List current as of Oct. 22, 2020.)

Friday, Nov. 13

8-8:45 a.m.

Move More Break

1:30-2:15 p.m.

Importance of Real-World Evidence in Understanding Current Lipid Management in Patients With ASCVD: A Focus on MI (LS.01)
Sponsored by Amgen, Inc.

1:30-2:15 p.m.

Selecting a First-Choice Therapy for Systolic HF: Meeting the Burden of Proof (LS.02)
Sponsored by Novartis Pharmaceuticals Corporation

1:30-2:15 p.m.

Transthyretin Cardiac Amyloidosis (ATTR-CM) Considerations and Clinical Challenges: Identifying, Confirming and Treating Patients (LS.03)
Sponsored by Pfizer, Inc.

2:30-3:15 p.m.

Exploring Worsening Heart Failure Events in Patients With Chronic Heart Failure With Reduced Ejection Fraction (LS.06)
Sponsored by Merck Sharp and Dohme Corp.

2:45-3:30 p.m.

The Next Horizon in the Heart Failure Treatment Paradigm for Patients With HFrEF: Results of the Landmark DAPA-HF Clinical Trial (LS.04)
Sponsored by AstraZeneca Pharmaceuticals LP

2:45-3:30 p.m.

The Cardiac Sarcomere in HFrEF and HCM: From Bedside to Bench (LS.05)
Sponsored by Cytokinetics, Inc.

5-6:30 p.m.*

Getting to the Heart of Diabetes: The Role of GLP-1 Receptor Agonists in Reducing Cardiovascular Risk (SS.07)
Sponsored by Lilly

5-6:30 p.m.*

Optimizing Outcomes in VTE Management: Collaborating Across the Continuum (SS.11)
Sponsored by The Bristol-Myers Squibb & Pfizer Alliance

Saturday, Nov. 14

8-8:45 a.m.

Move More Break

1:30-2:15 p.m.

VASCEPA® (icosapent ethyl): Elevating the Standard of Care (LS.07)
Sponsored by Amarin Parma, Inc.

1:30-2:15 p.m.

Jardiance® (empagliflozin) Tablets: The Impact of EMPA-REG OUTCOME (LS.08)
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc./Lilly USA

1:30-2:15 p.m.

How to Identify and Manage the Hypertrophic Cardiomyopathy (HCM) That Is Hiding (LS.09)
Sponsored by MyoKardia, Inc.

1:30-2:15 p.m.

HFpEF: Heart Failure With Preserved Ejection Fraction (HFpEF): Pathophysiology vs Outcomes Are We Narrowing the Gap? (LS.10)
Sponsored by Novartis Pharmaceuticals Corporation

2:45-3:30 p.m.

Getting to the Heart of Managing Heart Failure: Unmet Medical Need in HFrEF (LS.11)
Sponsored by Amgen, Inc.

2:45-3:30 p.m.

Clinical Insights in Chronic CAD/PAD: Reducing the Risk of Major Cardiovascular Events (LS.12)
Sponsored by Janssen Pharmaceuticals, Inc.

3:30-4:15 p.m.*

A New Horizon to Optimize AF Outcomes: Emerging Data and Techniques in Hybrid Ablation (SS.04)
Sponsored by AtriCure

5-6:30 p.m.*

The Heart, the Kidney, and SGLT2 Inhibition: From Clinical Trials to Patient Care (SS.06)
Sponsored by AstraZeneca Pharmaceuticals

5-6:30 p.m.*

A Case-Based Session Hosted by CPC Clinical Research on Thromboprophylaxis in COVID-19 With Live Discussion Among Experts in the Field, Including Leaders of Ongoing COVID-19 Antithrombotic Trials (SS.10)
Sponsored by CPC Clinical Research

5-6:30 p.m.*

Identifying Undiagnosed Nonvalvular Atrial Fibrillation in the Age of Telehealth: Novel Screening Technologies and Stroke Prevention Strategies (SS.12)
Sponsored by Bristol-Myers Squibb and Pfizer Alliance

Sunday, Nov. 15

8-8:45 a.m.

Move More Break

1:30-2:15 p.m.

Optimizing LDL-C Management in Recent MI Patients: A Focus on Clinical Data (LS.13)
Sponsored by Amgen, Inc.

1:30-2:15 p.m.

Clinical Insights in NVAF: Reducing the Risk of Stroke and Systemic Embolism (LS.14)
Sponsored by Janssen Pharmaceuticals, Inc.

1:30-2:15 p.m.

Heart Failure With Preserved Ejection Fraction: Current Perspectives and Opportunities to Optimize Care Surrounding Hospitalization (LS.15)
Sponsored by Novartis Pharmaceuticals Corporation

1:30-2:15 p.m.*

Calcitropes, Myotropes and Mitotropes: The Role of Emerging Therapies to Improve Systolic Function in HFrEF (SS.02)
Sponsored by Cytokinetics, Inc.

2:45-3:30 p.m.

Getting to the Heart of Managing Heart Failure: Advancements of Clinical Utility of HRQoL in HFrEF (LS.16)
Sponsored by Amgen, Inc.

2:45-3:30 p.m.

Improving Early Outcomes for the Post-AMI Patient: Cholesterol Efflux and the Role of ApoA-I in Plaque Stabilization (LS.17)
Sponsored by CSL Behring

5-6:30 p.m.*

Addressing the Impacts of Iron Deficiency in HF: Advances in Diagnosis and Management (SS.08)
Sponsored by American Regent

5-6:30 p.m.*

Improving Cardiovascular Outcomes by Decreasing Residual Risk (SS.13)
Sponsored by Amarin Pharma Inc.

5-6:45 p.m.*

National Heart, Lung, and Blood Institute (NHLBI) Company Showcase (SS.09)
Sponsored by National Heart, Lung, and Blood Institute

Monday, Nov. 16

8-8:45 a.m.

Move More Break

1:30-2:15 p.m.

An Approach to Managing Lipids: Oral, Nonstatin Therapies for Lowering LDL-C (LS.18)
Sponsored by Esperion Therapeutics, Inc.

1:30-2:15 p.m.

Intensive Lipid Management: Special Subgroups [Lp(a)] – Different Clinical Practices to Achieve the Same Therapeutic Targets (LS.19)
Sponsored by Kaneka Pharma America LLC

1:30-2:15 p.m.

Atherosclerotic Cardiovascular Disease (ASCVD) High Risk Assessment, Evaluation and Management (LS.20)
Sponsored by Novartis Pharmaceuticals Corporation

3:30-4:15 p.m.*

Mayo Clinic Cardiac Surgery Expertise in Surgical Treatment of Hypertrophic Cardiomyopathy, Aortic Aneurysms and Robotic Heart Surgery (SS.16)
Sponsored by Mayo Clinic Department of Cardiovascular Surgery

5-6:30 p.m.*

Antiplatelet Agent Updates: From Primary Prevention in CAD to Secondary Prevention of Stroke (SS.01)
Sponsored by AstraZeneca

5-6:30 p.m.*

Lowering LDL-C: When Statins Aren’t Enough (SS.14)
Sponsored by ESPERION Therapeutics, Inc.

Tuesday, Nov. 17

8-8:45 a.m.

Move More Break

1:30-2:15 p.m.

Role of Lipoprotein (a) in Atherosclerotic Cardiovascular Disease (LS.21)
Sponsored by Novartis Pharmaceuticals Corporation

2:30-3:15 p.m.

CCM® for Heart Failure – The Class Effect Assessing Heart Failure ­– How Are We Doing? Device Therapy for HF – Appropriate Patient Selection and Identification (LS.22)
Sponsored by Impulse Dynamics

5-6:30 p.m.*

Stepping Up Your Game for Management of Dyslipidemia (SS.03)
Sponsored by Amgen

5-6:30 p.m.*

The Role of Anticoagulants for Secondary Prevention in CAD and PAD Patients: When Should Therapy Be Initiated? (SS.15)
Sponsored by Janssen Scientific Affairs, LLC

 

Sessions noted with * indicate symposia. These events are not part of the official ScientificSessions as planned by the AHA Committee on Scientific Sessions Programming.